Home » Eli Lilly’s Zepbound Now Available in U.S. Pharmacies for $550 a Month

Eli Lilly’s Zepbound Now Available in U.S. Pharmacies for $550 a Month

by admin
Eli Lilly’s Zepbound Now Available in U.S. Pharmacies for $550 a Month

Eli Lilly’s Anti-Obesity Drug Zepbound Now Available in U.S. Pharmacies

Eli Lilly’s new anti-obesity drug Zepbound is now available in U.S. pharmacies, with the pharmaceutical company offering the drug at a discounted price for some insured customers. According to a company report released on Tuesday, insured customers may be able to purchase the drug for $550 a month, which is half the retail price.

The company has made the weight-loss drug available to adults through its commercial savings card program. Members with coverage can opt to pay as little as $25 for a 1- or 3-month prescription, making the drug more accessible for those with insurance.

For adults without commercial insurance, the cost for a one-month prescription can be up to $550.

Eli Lilly’s Zepbound was approved in November, marking a significant milestone in the fight against obesity. The drug is seen as a powerful new rival to Novo Nordisk’s Wegovy, and comes as a response to record obesity rates in the United States.

Lilly’s tirzepatide, the active ingredient in Zepbound, has already been available as Mounjaro for type 2 diabetes since 2022. It has been increasingly used for weight loss while awaiting anti-obesity approval.

The availability of Zepbound in U.S. pharmacies provides new options for individuals struggling with obesity, offering hope for more effective and accessible treatments for this widespread health issue.

See also  U.S. debt ceiling negotiations restart tonight Fed officials will speak intensively U.S. dollar index stands still Provider Investing.com

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy